Genetic mutations in both AGER and TGF-β receptors have been previously shown to increase the risk of various SCD complications, including stroke, priapism, infection, avascular necrosis, pulmonary hypertension, acute chest syndrome, and acute pain crises [12,13]. This evidence concerns the gene AGER and stroke disorder.